VANCOUVER, BC / ACCESSWIRE / June 2, 2017 / CVR Medical Corp. (TSX.V:CVM) (FRANKFURT: B3BN) (OTCQB: CRRVF) (“CVR Medical“) is pleased to announce that CVR Medical has obtained TSX Venture Exchange approval to issue 243,850 common shares of CVR Medical at a deemed price of $0.3375 per share (the “Shares”), as payment to the Lubow Group that was due for their consulting services pursuant to a consulting agreement with an effective date of January 12, 2017. The Shares are subject to a four month hold period expiring on September 30, 2017.
For additional information on the organization, leadership, and current news please visit the newly launched company website www.CVRMed.com
About CVR Medical
CVR Medical is a company that is involved in an equal parts joint venture with CVR Global Inc. (the “Joint Venture”). The Joint Venture operates in the medical industry focused on the commercialization of a proprietary subsonic, infrasonic, and low frequency sound wave analysis technology and has patents to a diagnostic device designed to detect and measure carotid arterial stenosis. CVR Medical is managed by a proven technical team. CVR Medical trades on the TSX Venture Exchange under the symbol CVM.
For further information contact:
Brisco Capital Partners Corp.
Scott Koyich, President
Telephone: (403) 262-9888